Bukwang Pharmaceutical IND부광약품
003000 · KOSPI · ₩003000 · 부광약품
₩3,750▼ ₩5 (0.13%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩201B | ₩160B | ₩126B | ₩191B | ₩182B |
| Cost of sales | ₩109B | ₩86B | ₩79B | ₩111B | ₩107B |
| Gross profit | ₩92B | ₩74B | ₩47B | ₩79B | ₩76B |
| Operating income | ₩14B | ₩1.6B | −₩37B | −₩231M | ₩5.6B |
| Net income | ₩12B | −₩3.5B | −₩34B | −₩4.2B | −₩2.8B |
| Net income to shareholders | ₩13B | −₩2.6B | −₩31B | −₩2.5B | −₩917M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩476B | ₩373B | ₩429B | ₩401B | ₩397B |
| Current assets | ₩303B | ₩204B | ₩254B | ₩219B | ₩220B |
| Cash and equivalents | ₩96B | ₩90B | ₩151B | ₩86B | ₩83B |
| Total liabilities | ₩135B | ₩129B | ₩195B | ₩129B | ₩117B |
| Current liabilities | ₩118B | ₩35B | ₩98B | ₩45B | ₩37B |
| Borrowings | ₩80B | ₩79B | ₩79B | ₩0 | ₩0 |
| Total equity | ₩341B | ₩244B | ₩234B | ₩272B | ₩280B |
| Shareholders' equity | ₩341B | ₩244B | ₩226B | ₩263B | ₩270B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩21B | ₩34B | −₩9.4B | ₩16B | ₩27B |
| Capital spending | ₩7.3B | ₩1.9B | ₩2.8B | ₩3.2B | ₩785M |
| Free cash flow | ₩14B | ₩32B | −₩12B | ₩13B | ₩26B |
| Dividends paid | ₩4.9B | ₩0 | ₩0 | ₩6.8B | ₩6.2B |
Consolidated where available. Amounts in won.
Also known as: Bukwang Pharmaceutical IND / 부광약품 / 003000 / KRX:003000
Source: KRX statistical information